Daiichi Sankyo's stock dropped 25% due to disappointing clinical data, but upcoming studies could drive a rebound for ...

Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

With a market cap of $252.6 billion, Rahway, New Jersey-based Merck & Co., Inc. (MRK) is a global leader in the healthcare ...

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

Atropos Health Collaborates with Merck for Rapid Evidence Generation to Accelerate Innovation for Life-Saving Treatments ...

The recipient in Changsha, the capital of Hunan province, became the first man on the Chinese mainland to receive the HPV ...

Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...

Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).

The American Chamber of Commerce in Vietnam has appointed doctor Dam Thi Hoang Lan, with decades of experience in healthcare, as its new chair.

The Prevnar 20 approval comes a few weeks ahead of an FDA decision on Merck's V114, which was granted a priority review by the regulator in January for the prevention of IPD in adults.

GSK, Pfizer, Johnson & Johnson, Reynolds American, Novartis, Imperial Brands, Cipla Limited, British American Tobacco, Merck ...